BRIEF-Exelixis says European commission approves Cabometyx
September 14, 2016 at 01:15 AM EDT
* European Commission approves Cabometyx tablets for the treatment of advanced renal cell carcinoma following VEGF-targeted therapy
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.